[صفحه اصلی ]   [Archive]  
:: صفحه اصلي :: درباره نشريه :: آخرين شماره :: تمام شماره‌ها :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
بخش‌های اصلی
صفحه اصلی::
اطلاعات نشریه::
برای نویسندگان::
آرشیو مجله و مقالات::
برای داوران::
ثبت نام و اشتراک::
تماس با ما::
تسهیلات پایگاه::
بایگانی مقالات زیر چاپ::
::
جستجو در پایگاه

جستجوی پیشرفته
..
دریافت اطلاعات پایگاه
نشانی پست الکترونیک خود را برای دریافت اطلاعات و اخبار پایگاه، در کادر زیر وارد کنید.
..
:: دوره 11، شماره 4 - ( 4-1399 ) ::
جلد 11 شماره 4 صفحات 369-355 برگشت به فهرست نسخه ها
KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
چکیده:   (3868 مشاهده)
Background: Mutations in the EGFR signaling pathway play an important role in the development of colorectal cancer (CRC). Mutations in these genes, like KRAS and BRAF, affect the treatment strategies and associated with poor prognosis and relative resistance to anti-EGFR therapies. Our aim was to conduct a systematic and meta-analysis on all studies that have been conducted on the prevalence of these gene mutations in Iranian CRC patients.
Methods: Four science citation index databases (MEDLINE, EMBASE, Web of Science and Cochrane library) and local databases were searched up to March 2018 with related keywords. Two reviewers independently screened and extracted the data. Quality of all included studies was assessed using an adapted checklist from STROBE. A random-effect model was used to calculate the total prevalence of KRAS and BRAF mutations in CRC subjects by the event rate (ER). Meta-regression was utilized to explore heterogeneity causes.
Results: In total, from 573 records, 23 eligible studies (2662 patients) were included for data extraction and analysis. In 18 of 23 included studies, the prevalence of KRAS mutations was 33.9% (95% CI=30.1-37.9) with I2=65.17 (p<0.001). The occurrence of KRAS mutations in codon 12 and 13 was 76.9% (95% CI = 70.4-82.3%) with I2=84.88 (p<0.001) and 23.5% (95% CI=17.9-30.3) with I2=85.85 (p<0.001), respectively. In 9 of 23 studies, the BRAF mutation rate was 3.2% (95% CI=0.003-13.6) with I2=88.61 (p<0.001).
Conclusion: The prevalence of these mutations in CRC patients shows a significant difference in the different regions of Iran, which is probably due to environmental and racial factors.
متن کامل [PDF 726 kb]   (1163 دریافت)    
نوع مطالعه: Review Article |
دریافت: 1397/10/28 | پذیرش: 1398/12/19 | انتشار: 1396/4/24
ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

CAPTCHA



XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yari A, Afzali A, Aalipour M, Nakheai M, Zahedi M J. KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian J Intern Med 2020; 11 (4) :355-369
URL: http://caspjim.com/article-1-1728-fa.html

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. 1. 1399; 11 (4) :355-369

URL: http://caspjim.com/article-1-1728-fa.html



بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.
دوره 11، شماره 4 - ( 4-1399 ) برگشت به فهرست نسخه ها
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 37 queries by YEKTAWEB 4645